Business Context and Reporting Period
Company: Kewaunee Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: April 30, 2009
Business Overview: The Company designs, manufactures, and installs laboratory and technical furniture, including cabinetry, fume hoods, and workstations. Products are sold primarily to pharmaceutical, biotechnology, educational, and healthcare sectors. Operations are divided into Domestic and International segments, with significant reliance on competitive public bidding and construction project timelines.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Sales | $103,978,000 | $89,510,000 |
| Gross Profit | $21,373,000 | $19,172,000 |
| Gross Margin | 20.6% | 21.4% |
| Operating Earnings | $7,084,000 | $5,613,000 |
| Net Earnings | $4,247,000 | $3,134,000 |
| Diluted EPS | $1.66 | $1.23 |
| Operating Cash Flow | $2,100,000 | $3,391,000 |
| Working Capital | $18,882,000 | $15,920,000 |
| Total Debt (Long-term + Short-term) | $11,861,000 | $9,578,000 |
| Order Backlog | $62.7 million | $58.7 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% to $104.0 million, driven by a 22% increase in Domestic Operations ($90.3 million). This growth offset a 13% decline in International Operations ($13.7 million) due to a soft Asian marketplace.
- Margin Compression: Gross profit margin decreased from 21.4% to 20.6%. Management attributed this to higher raw material costs (steel, wood, epoxy resin), increased energy and transportation costs, and competitive pricing pressures.
- Operating Expenses: Increased to $14.3 million (13.7% of sales) from $13.6 million. Increases were driven by higher pension expense ($161,000), depreciation on computer systems ($175,000), and sales commissions ($116,000).
- Interest Expense: Decreased to $280,000 from $294,000, primarily due to lower interest rates.
- Liquidity: Working capital increased to $18.9 million, with a current ratio improving to 2.0-to-1. Cash flow from operations declined to $2.1 million, impacted by increases in accounts receivable and inventory.
Outlook, Risks, and Management Commentary
- Outlook: Management expects fiscal year 2010 to be profitable. Capital expenditures are anticipated to be approximately $2.0 million, funded by operating cash flows.
- Economic Risks: The Company faces uncertainty due to disruptions in global financial markets and potential economic recessions, which could adversely affect demand for laboratory construction projects.
- Cost Pressures: The Company bears the risk of rising labor and material costs between order quotation and delivery, as prices are typically quoted on a firm basis. Inability to pass these costs to customers could materially affect profitability.
- Pension Costs: The Company expects higher pension costs in fiscal 2010 resulting from investment losses in the pension portfolio during fiscal 2009.
- Customer Concentration: Sales to one national distributor, VWR International, LLC, represented approximately 13% of total sales for fiscal 2009. Loss of this customer would have a material effect on revenues.
- Backlog: The order backlog of $62.7 million is scheduled primarily for shipment in fiscal 2010, though delays in construction projects may impact timing.
Investor Verification Checklist
- Raw Material Costs: Verify the trajectory of steel, wood, and resin prices and the Company's ability to implement price increases to maintain margins.
- Construction Pipeline: Assess the health of the laboratory construction industry and the risk of project delays impacting revenue recognition from the $62.7 million backlog.
- Pension Liability: Review the funded status of the pension plan and the projected impact of actuarial losses on future operating expenses.
- International Exposure: Monitor the recovery of the Asian marketplace, which saw a 13% sales decline in fiscal 2009.
- Credit Facility: Confirm the status of the $14 million revolving credit facility, which matures in September 2010, and the Company's compliance with financial covenants.